United Therapeutics Co. (UTHR) Shares Sold by UBS Asset Management Americas Inc.
UBS Asset Management Americas Inc. decreased its position in United Therapeutics Co. (NASDAQ:UTHR) by 4.2% during the 4th quarter, Holdings Channel reports. The firm owned 119,449 shares of the biotechnology company’s stock after selling 5,288 shares during the period. UBS Asset Management Americas Inc.’s holdings in United Therapeutics were worth $17,672,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Teacher Retirement System of Texas purchased a new position in United Therapeutics in the fourth quarter valued at approximately $1,812,000. California Public Employees Retirement System lifted its stake in United Therapeutics by 1.5% in the third quarter. California Public Employees Retirement System now owns 133,793 shares of the biotechnology company’s stock valued at $15,679,000 after purchasing an additional 1,993 shares during the last quarter. KBC Group NV lifted its stake in United Therapeutics by 3.5% in the third quarter. KBC Group NV now owns 22,974 shares of the biotechnology company’s stock valued at $2,692,000 after purchasing an additional 783 shares during the last quarter. Swiss National Bank lifted its stake in United Therapeutics by 1.0% in the third quarter. Swiss National Bank now owns 165,600 shares of the biotechnology company’s stock valued at $19,407,000 after purchasing an additional 1,600 shares during the last quarter. Finally, Van ECK Associates Corp lifted its stake in United Therapeutics by 9.4% in the third quarter. Van ECK Associates Corp now owns 123,100 shares of the biotechnology company’s stock valued at $14,426,000 after purchasing an additional 10,598 shares during the last quarter. Institutional investors and hedge funds own 99.85% of the company’s stock.
Several equities analysts recently commented on UTHR shares. Barclays reiterated an “underweight” rating and issued a $105.00 price objective (down previously from $115.00) on shares of United Therapeutics in a research note on Thursday, February 22nd. Credit Suisse Group reissued an “underperform” rating and set a $115.00 target price (down previously from $120.00) on shares of United Therapeutics in a report on Thursday, February 22nd. ValuEngine cut shares of United Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. TheStreet raised shares of United Therapeutics from a “c+” rating to a “b” rating in a report on Friday, December 15th. Finally, BidaskClub cut shares of United Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, February 24th. Five investment analysts have rated the stock with a sell rating, four have issued a hold rating and three have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $135.20.
Shares of United Therapeutics Co. (NASDAQ:UTHR) opened at $113.79 on Monday. The company has a current ratio of 3.26, a quick ratio of 3.01 and a debt-to-equity ratio of 0.12. United Therapeutics Co. has a 1-year low of $111.11 and a 1-year high of $152.55. The stock has a market cap of $4,920.25, a price-to-earnings ratio of 10.37 and a beta of 1.32.
United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.59 by $0.30. The business had revenue of $464.70 million for the quarter, compared to analysts’ expectations of $420.55 million. United Therapeutics had a net margin of 24.22% and a return on equity of 24.41%. The business’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $4.12 EPS. equities research analysts forecast that United Therapeutics Co. will post 12.46 earnings per share for the current fiscal year.
WARNING: This story was originally posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was stolen and republished in violation of U.S. & international trademark & copyright laws. The original version of this story can be viewed at https://www.watchlistnews.com/united-therapeutics-co-uthr-shares-sold-by-ubs-asset-management-americas-inc/1908972.html.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.